Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

ACAD | Acadia Pharmaceuticals Inc

Index	RUT	P/E	-	EPS (ttm)	-0.68	Insider Own	0.77%	Shs Outstand	163.73M	Perf Week	-3.31%
Market Cap	3.87B	Forward P/E	34.65	EPS next Y	0.68	Insider Trans	104.80%	Shs Float	162.47M	Perf Month	-17.38%
Income	-110.81M	PEG	-	EPS next Q	-0.42	Inst Own	97.78%	Short Float / Ratio	6.27% / 6.26	Perf Quarter	-2.44%
Sales	550.90M	P/S	7.02	EPS this Y	69.68%	Inst Trans	0.92%	Short Interest	10.18M	Perf Half Y	27.04%
Book/sh	2.42	P/B	9.75	EPS next Y	-	ROA	-17.65%	Target Price	30.33	Perf Year	41.07%
Cash/sh	2.29	P/C	10.31	EPS next 5Y	-	ROE	-26.68%	52W Range	13.73 - 33.99	Perf YTD	48.43%
Dividend	-	P/FCF	-	EPS past 5Y	10.76%	ROI	-24.87%	52W High	-30.48%	Beta	0.61
Dividend %	-	Quick Ratio	2.57	Sales past 5Y	35.48%	Gross Margin	97.52%	52W Low	72.10%	ATR	0.84
Employees	513	Current Ratio	2.62	Sales Q/Q	22.79%	Oper. Margin	-23.14%	RSI (14)	31.22	Volatility	3.19% 3.11%
Optionable	Yes	Debt/Eq	0.15	EPS Q/Q	-	Profit Margin	-20.12%	Rel Volume	1.75	Prev Close	23.29
Shortable	Yes	LT Debt/Eq	0.13	Earnings	Aug 02 AMC	Payout	-	Avg Volume	1.63M	Price	23.63
Recom	2.18	SMA20	-8.56%	SMA50	-14.96%	SMA200	6.46%	Volume	2,849,795	Change	1.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12
Nov-01-22	Initiated	Loop Capital	Hold	$17
Aug-08-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Aug-05-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15
Jun-21-22	Downgrade	Jefferies	Buy → Underperform	$25 → $10
Jun-16-22	Upgrade	Jefferies	Hold → Buy	$25
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy	$30 → $31
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$36
Jan-05-22	Upgrade	Citigroup	Neutral → Buy	$30
Dec-21-21	Downgrade	Guggenheim	Buy → Neutral	$28
Nov-01-21	Upgrade	Guggenheim	Neutral → Buy	$23
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$20
Sep-23-21	Resumed	Needham	Hold
Jun-10-21	Initiated	Berenberg	Hold	$29
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral	$43 → $18
Apr-06-21	Downgrade	Mizuho	Buy → Neutral	$37 → $25
Apr-06-21	Downgrade	Jefferies	Buy → Hold	$40 → $21
Apr-06-21	Downgrade	Goldman	Buy → Neutral	$73 → $25
Apr-06-21	Downgrade	Canaccord Genuity	Buy → Hold	$40 → $26

Show Previous Ratings

Sep-22-23 06:23PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-23 04:05PM	Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications (Business Wire)
Aug-30-23 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-28-23 06:00PM	2 Supercharged Growth Stocks Billionaires Can't Stop Buying (Motley Fool)
Aug-22-23 08:30AM	Can This Red-Hot Biotech Stock Keep Beating the Broader Markets? (Motley Fool)
10:44AM	Loading…
Aug-19-23 10:44AM	Billionaire Stan Druckenmillers Small-Cap Stock Picks (Insider Monkey)
Aug-14-23 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-04-23 12:36PM	Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform (Zacks)
Aug-02-23 04:26PM	Acadia: Q2 Earnings Snapshot (AP Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview (Business Wire)
Aug-01-23 07:30PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-23 11:21AM	Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts (Zacks)
Jul-24-23 04:05PM	Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer (Business Wire)
Jul-21-23 09:40AM	Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-19-23 04:04PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023 (Business Wire)
08:19AM	Loading…
Jul-15-23 08:19AM	Analysts Just Published A Bright New Outlook For ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) (Simply Wall St.)
Jul-14-23 04:04PM	Acadia's Newest Drug Just Obliterated Sales Expectations; Shares Hit Two-Year High (Investor's Business Daily) +24.73%
11:41AM	Why Acadia Pharmaceuticals Stock Is Soaring Today (Motley Fool)
Jul-13-23 07:11PM	Why These 2 Biotech Stocks Made Big Moves Late Thursday (Motley Fool)
04:05PM	Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neurens NNZ-2591 in Rett Syndrome and Fragile X Syndrome (Business Wire)
Jun-26-23 05:00PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-13-23 04:05PM	Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome (Business Wire)
Jun-12-23 01:24PM	ACADIA Pharmaceuticals (NASDAQ:ACAD) delivers shareholders favorable 9.3% CAGR over 5 years, surging 3.1% in the last week alone (Simply Wall St.)
Jun-08-23 11:10AM	Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE (trofinetide) Efficacy and Safety in Patients with Rett Syndrome (Business Wire)
Jun-07-23 11:30AM	Acadia (ACAD) Up 12% Since Last Earnings Report: Can It Continue? (Zacks)
05:58AM	3 Penny Stocks That Could Skyrocket in the Next 12 Months (InvestorPlace)
Jun-01-23 09:04AM	Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-08-23 05:25PM	Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:13PM	Acadia: Q1 Earnings Snapshot (AP Finance)
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview (Business Wire)
09:21AM	Loading…
09:21AM	ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Is Matching Sentiment Around Its Revenues (Simply Wall St.)
May-05-23 04:04PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-02-23 09:04AM	Acadia Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Apr-25-23 09:04AM	Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023 (Business Wire)
Apr-20-23 09:04AM	Acadia Pharmaceuticals to Present DAYBUE (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting (Business Wire)
Apr-17-23 09:04AM	Acadia Pharmaceuticals Announces DAYBUE (trofinetide) is Now Available for the Treatment of Rett Syndrome (Business Wire) +7.67%
Apr-11-23 09:04AM	Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference (Business Wire)
07:44AM	ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shift From Loss To Profit (Simply Wall St.)
Mar-13-23 12:56PM	Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment (Benzinga)
12:11PM	Acadias rare-disease drug to cost $575,000 to $595,000 (MarketWatch)
Mar-10-23 09:45PM	Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older (Business Wire)
Mar-07-23 09:45AM	1 Top Biotech Stock to Buy in March (Motley Fool)
Mar-02-23 05:45AM	ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 05:41AM	ACADIA Pharmaceuticals Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Feb-28-23 04:00PM	Analysts See Steady Growth For Acadia Pharma's Nuplazid (Benzinga) +6.65%
09:26AM	Q4 2022 ACADIA Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-23 05:25PM	Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview (Business Wire)
Feb-20-23 10:00AM	Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-14-23 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (Business Wire)
Feb-13-23 04:15PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-23 09:00AM	Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development (Business Wire)
Jan-03-23 11:58AM	Investors in ACADIA Pharmaceuticals (NASDAQ:ACAD) from three years ago are still down 62%, even after 4.1% gain this past week (Simply Wall St.)
09:00AM	Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinsons Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics (Business Wire)
08:28AM	Acadia Pharmaceuticals Bulls Will Need to Be Patient for Now (TheStreet.com)
Dec-21-22 04:05PM	Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 (Business Wire)
Nov-08-22 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire) +5.59%
Nov-03-22 12:23PM	Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss (Zacks) -6.97%
Nov-02-22 05:35PM	Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results (Business Wire)
Nov-01-22 10:04AM	Is a Surprise Coming for Acadia Pharmaceuticals (ACAD) This Earnings Season? (Zacks)
Oct-27-22 04:05PM	Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic (Business Wire)
10:02AM	Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-26-22 10:02AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:11AM	Breakeven On The Horizon For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) (Simply Wall St.)
Oct-20-22 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022 (Business Wire)
Oct-19-22 12:02PM	AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem (Zacks)
Oct-13-22 07:30AM	Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors (Business Wire)
Oct-12-22 10:57AM	Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern (Zacks)
Oct-06-22 01:36PM	Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why (Zacks)
Oct-04-22 02:19PM	Why Acadia Pharmaceuticals Stock's Rally Could Have Legs (Schaeffer's Investment Research) +5.99%
07:30AM	Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed (Business Wire)
Sep-13-22 08:44AM	Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review (Zacks) -5.64%
Sep-12-22 07:30AM	Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA (Business Wire)
Sep-07-22 11:30AM	Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-01-22 09:03AM	Acadia Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-22 09:55AM	Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade (Zacks)
Aug-26-22 12:00PM	Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-09-22 01:24PM	Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data (Benzinga)
11:06AM	Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates (Zacks)
Aug-08-22 05:35PM	Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-05-22 07:55AM	FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions (Benzinga) +5.25%
Aug-04-22 11:39PM	UPDATE 1-U.S. FDA declines to approve expanded use of Acadia's antipsychotic drug (Reuters)
11:05PM	Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimers Disease Psychosis (Business Wire)
Aug-01-22 10:01AM	Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-27-22 08:23AM	Investors five-year losses grow to 52% as the stock sheds US$212m this past week (Simply Wall St.)
Jul-25-22 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022 (Business Wire)
Jul-19-22 11:22AM	Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate (Zacks)
Jul-18-22 04:07PM	Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome (Business Wire)
Jul-08-22 11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why (Zacks)
Jun-21-22 12:07PM	Why Acadia Pharmaceuticals Stock Is Crashing Today (Motley Fool) -33.32%
08:27AM	Why Acadia Pharma Shares Are Plunging Today (Benzinga)
07:56AM	Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee vote (MarketWatch)
Jun-17-22 08:00PM	Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimers Disease Psychosis (Business Wire)
07:14AM	Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis (MarketWatch)
07:05AM	Acadia Pharmaceuticals Stock Trading Halted Today (Business Wire)
Jun-16-22 03:42PM	HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate (Benzinga)
10:42AM	Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA (Zacks)
Jun-15-22 04:53PM	Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug (Investor's Business Daily) +15.51%

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kihara James	Principal Accounting Officer	Sep 15	Sale	25.88	2,000	51,760	10,778	Sep 19 06:31 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Aug 21	Sale	29.00	10,000	289,970	15,682	Aug 23 07:31 PM
DAVIS STEPHEN	CEO	Jul 14	Option Exercise	20.77	100,000	2,077,000	136,695	Jul 18 06:00 PM
DAVIS STEPHEN	CEO	Jul 14	Sale	30.04	100,000	3,004,350	36,695	Jul 18 06:00 PM
DAVIS STEPHEN	CEO	Jul 12	Sale	25.05	55,104	1,380,449	36,695	Jul 13 08:27 PM
DAVIS STEPHEN	CEO	Jul 11	Sale	25.00	16,498	412,450	91,799	Jul 13 08:27 PM
Kihara James	Principal Accounting Officer	Jun 15	Sale	24.15	2,000	48,300	9,144	Jun 16 04:38 PM
Brege Laura	Director	Jun 12	Sale	24.87	4,500	111,906	13,502	Jun 14 05:14 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 08	Option Exercise	0.00	1,893	0	23,798	Jun 12 08:48 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 08	Sale	25.02	974	24,369	22,824	Jun 12 08:48 PM
BAKER BROS. ADVISORS LP	Director	May 24	Buy	25.48	553,263	14,096,825	39,317,673	May 24 05:09 PM
BAKER BROS. ADVISORS LP	Director	May 23	Option Exercise	17.01	25,000	425,250	38,620,261	May 24 05:09 PM
BAKER BROS. ADVISORS LP	Director	May 23	Buy	25.41	209,053	5,312,458	38,811,515	May 24 05:09 PM
BAKER BROS. ADVISORS LP	Director	May 22	Buy	24.57	134,206	3,297,815	38,607,761	May 24 05:09 PM
Schneyer Mark C.	EVP, Chief Financial Officer	May 17	Sale	22.50	15,310	344,475	21,905	May 19 06:48 PM
Teehan Brendan	EVP, COO, Head of Commercial	May 17	Sale	22.50	14,869	334,552	24,356	May 19 06:43 PM
Kihara James	Principal Accounting Officer	May 17	Sale	22.50	5,947	133,808	11,144	May 19 06:54 PM
DAVIS STEPHEN	CEO	May 01	Sale	21.18	7,806	165,331	108,297	May 02 07:02 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	May 01	Sale	21.18	917	19,422	25,513	May 02 07:06 PM
Teehan Brendan	EVP, COO, Head of Commercial	May 01	Sale	21.18	548	11,607	9,487	May 02 07:04 PM
Teehan Brendan	EVP, COO, Head of Commercial	Apr 29	Option Exercise	0.00	1,567	0	10,035	May 02 07:04 PM
DAVIS STEPHEN	CEO	Apr 29	Option Exercise	0.00	15,625	0	116,103	May 02 07:02 PM
Kihara James	Principal Accounting Officer	Apr 10	Sale	18.14	523	9,487	5,197	Apr 11 09:15 PM
DAVIS STEPHEN	CEO	Apr 06	Sale	18.16	8,582	155,849	100,478	Apr 07 08:34 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Apr 06	Sale	18.16	1,916	34,795	7,477	Apr 07 08:37 PM
Teehan Brendan	EVP, COO, Head of Commercial	Apr 06	Sale	18.16	1,751	31,798	8,468	Apr 07 08:44 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Apr 06	Sale	18.16	1,456	26,441	23,425	Apr 07 08:32 PM
Kihara James	Principal Accounting Officer	Apr 06	Sale	18.16	701	12,730	4,231	Apr 07 08:41 PM
DAVIS STEPHEN	CEO	Feb 24	Sale	18.78	3,851	72,322	91,727	Feb 27 09:00 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Feb 24	Sale	18.78	803	15,080	20,108	Feb 27 09:00 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Feb 24	Sale	18.78	577	10,836	4,118	Feb 27 09:00 PM
Teehan Brendan	EVP, COO, Head of Commercial	Feb 24	Sale	18.78	461	8,658	5,195	Feb 27 09:00 PM
Kihara James	Principal Accounting Officer	Feb 24	Sale	18.78	350	6,573	2,923	Feb 27 09:00 PM
Brege Laura	Director	Jan 12	Option Exercise	17.01	12,500	212,625	12,500	Jan 17 05:17 PM
BAKER BROS. ADVISORS LP	Director	Jan 12	Option Exercise	5.22	30,000	156,600	38,484,981	Jan 17 04:22 PM
Brege Laura	Director	Jan 12	Sale	18.25	12,500	228,125	0	Jan 17 05:17 PM
DAVIS STEPHEN	CEO	Jan 09	Sale	17.13	3,904	66,877	84,633	Jan 10 08:38 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Jan 09	Sale	17.13	589	10,090	18,697	Jan 10 08:20 PM
Teehan Brendan	EVP, COO, Head of Commercial	Jan 09	Sale	17.13	532	9,113	4,549	Jan 10 08:30 PM
Stankovic Srdjan R.	President	Nov 21	Sale	15.07	1,847	27,834	61,234	Nov 22 04:34 PM
DAVIS STEPHEN	CEO	Oct 15	Sale	15.81	2,804	44,331	79,009	Oct 18 09:16 PM
Stankovic Srdjan R.	President	Oct 15	Sale	15.81	1,326	20,964	56,831	Oct 18 09:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACAD | Acadia Pharmaceuticals Inc

Upgrade your FINVIZ experience